PharmaEssentia Corp (藥華醫藥) yesterday said it expects to gain marketing approval in Europe before the end of the third quarter next year for its new P1101 polycythemia vera (PV) drug.
The company is also seeking approval from US authorities for the drug.
PharmaEssentia reported favorable outcomes of its 12-month and a 24-month phase III clinical studies for P1101 at this year’s American Society of Hematology annual meeting, with both demonstrating superiority over other treatment options.
The drug, which is to be marketed as Ropeginterferon-alfa-2b (Ropeg), is classified as an orphan drug for PV, a rare blood disease.
In light of favorable clinical study results, Ropeg could become the mainstream first-line treatment for PV, PharmaEssentia chief executive officer Lin Ko-Chung (林國鐘) said.
While the company has formed a partnership with Austria-based AOP Orphan Pharmaceuticals AG to oversee market approval and sales of Ropeg in Europe, it is confident it can handle the US market internally.
The company is familiar with the US market, as much of its senior management team has extensive experience at US pharmaceutical companies and at the US Food and Drug Administration, it said.
“We have a close-knit network of physicians and patients in the US,” PharmaEssentia general manager Jack Hwang (黃正谷) said at a news conference in Taipei, adding that in most cases, PV patients are referred to hematology specialists for treatment.
The US-based Myeloproliferative Neoplasms Research Foundation has also voiced its support for Ropeg, Hwang said.
Ropeg is an interferon with milder side effects than other treatment options, such as hydroxyurea, a first-line chemotherapy, and Pegasys (peginterferon alfa-2a), an interferon.
Patients who have exhausted first-line options usually move on to Jakafi (ruxolitinib).
The company has hired Marija Sebastian, a former Novartis AG executive who oversaw global sales of Jakavi, to lead its US sales operation, Hwang said.
Formulated with the company’s proprietary pegylation technology platform, Ropeg consists of a single isomer, compared with eight in Pegasys, and its improved purity takes a lesser toll on users, PharmaEssentia said.
An improved safety profile also enables users to tolerate higher doses, cutting down the required regiment from weekly injections to biweekly injections, it said.
Ropeg has also been found to reduce the likelihood of mutations in the JAK2 gene, a condition that is associated with PV, it added.
The drug is expected to be priced between US$60,000 and US$100,000, compared with US$130,000 for Jakavi, PharmaEssentia investor relations director Ku Shan-chi (古珊綺) said, adding that about 85,000 people have been diagnosed with PV in the US.
Meanwhile, the company also plans to expand Ropeg’s indications to include essential thrombocythemia, Ku said.
‘ACCORDING TO PLAN’: A company official said that it has set up production sites worldwide to provide services and that its Wisconsin project was going smoothly Hon Hai Precision Industry Co’s (鴻海精密) smart manufacturing center in Wisconsin would begin trial manufacturing in the middle of this year, the company said yesterday, adding that it plans to build a research institute to develop key technologies to support growth over the next five years. Hon Hai, known internationally as Foxconn Technology Group (富士康科技集團), said in an annual report submitted to the Taiwan Stock Exchange that its planned Foxconn Institute for Research in Science and Technology would conduct research into artificial intelligence, next-generation communications, quantum computing, cybersecurity and nano semiconductors in Taiwan. Hon Hai is to make products at the center
TV and online retailer Momo.com Inc (富邦媒體) yesterday said it has set up a new logistics subsidiary, Fu Sheng Logistics Co (富昇物流), to oversee the company’s extensive shipping operations. Leveraging Momo’s 23 satellite warehouses and distribution centers nationwide, Fu Sheng will be in charge of executing the retailer’s same-day shipment plan for deliveries in Taipei, New Taipei City, Taoyuan, Taichung, Tainan and Kaohsiung, Momo said in a press release. Seeking to further shorten its supply chain, the company is to set up another seven satellite warehouses and distribution centers by the end of the year. “Fu Sheng has a fleet of 200 couriers
E Ink Holdings Inc (元太科技), the world’s sole supplier of e-paper displays for e-readers and shelf labels, posted its best quarterly net profit for the first quarter in nine years amid increased demand during a traditionally slow season. Net profit soared 80 percent to NT$787 million (US$26.23 million) in the quarter ended March 31, compared with NT$438 million a year earlier. That translated into earnings per share of NT$0.69, up from NT$0.39. E Ink posted lower royalty income of NT$371.23 million last quarter from NT$448.74 million a year earlier, a company financial statement showed. E Ink said that it expects royalty income to
STAYING AHEAD: Fitch said that TSMC remains technologically ahead of others, but Samsung is building a new chip fab, while China is investing in its domestic industry As escalating US-China tensions and COVID-19-related production disruptions force US technology supply chains to transform, Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) US$12 billion chip fabrication plant in Arizona would be key to spurring greater US production of core semiconductor components, Fitch Ratings said. “We view the US-TSMC alliance as a first step in building a more autonomous US technology supply chain, given high barriers to entry, specifically related to the significant capital and design capability required for leading-edge semiconductor manufacturing,” Fitch said in a statement on Tuesday. “By working with TSMC, US chipmakers will not face the financial burden of incremental investment